⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565996 | 0.86 | DPP4 (0.37) | — | |
| SCHEMBL17630812 | 0.81 | — | — | |
| SCHEMBL24616328 | 0.74 | — | — | |
| SCHEMBL101460 | 0.73 | — | — | |
| SCHEMBL4126698 | 0.69 | — | — | |
| SCHEMBL101752 | 0.69 | — | — | |
| SCHEMBL12077935 | 0.68 | — | — | |
| SCHEMBL20742567 | 0.68 | — | — | |
| SCHEMBL1192219 | 0.68 | AOC2 (0.34) | — | |
| SCHEMBL24711335 | 0.68 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250221996-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-07-10 | — | — | US | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023239729-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-14 | — | — | WO | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |